Investigators sought to determine the long-term safety and efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression.
All articles by M Tewar, MD
Mark Zimmerman, MD, discusses controversies related to categorizing severity and identifying optimal treatment of depression.
By
Publish Date
-
Latest News Your top articles for Friday
For More Personalized News -
Haymarket Medical NetworkTop Picks
-
Spotlight Course
- Loading...
Continuing Medical Education (CME/CE) Courses